This study compared the number, type, and time spent on interventions for patients filling non-MS neurology specialty medications at IHSSPs versus non-IHSSP pharmacies. IHSSP patients experienced greater variety and frequency of clinical interventions, including a third of interventions related to therapy changes which could impact patient outcomes. Financial assistance recommendations were more necessary for non-IHSSP patients.

There is a growing number of specialty medications with requirements that exceed standard characteristics, newly defined as "ultra-complex." This article details ultra-complex specialty medications, and strategies implemented by VSP to maintain an optimal patient journey. Ultra-complex specialty medications provide unprecedented therapeutic advancements but demand multidisciplinary resources to reach the desired therapeutic goals, which make health systems an ideal management setting.

This study found that health system specialty pharmacist interventions in MS can lead to substantial direct and indirect cost avoidance-up to $156,265 within a 6-month time frame. Most costs were avoided directly by preventing the dispensing of inappropriate therapies and indirectly by preventing additional health care utilization.

This case series identified patients with multiple sclerosis whose lymphocyte counts were stable on dimethyl fumarate, and then subsequently developed lymphopenia after switching to diroximel fumarate, prompting its discontinuation.

We compared rates of PMN, TAT, PDC, and persistence between an HSSP and external specialty pharmacies. Prescriptions sent to non-HSSP specialty pharmacies 60% more likely to experience PMN than prescriptions sent to an HSSP. Patients filling with an HSSP had higher adherence. Patients with inflammatory conditions filling with the HSSP had shorter turnaround time and higher persistence. Patients with MS who filled with the HSSP had higher PDC.

This study assessed patients' satisfaction and barriers to their current UC or IBD treatment, their perceived quality of life, and pill burden associated with their current treatment. Patients are open to deprescribing their 5-ASA but would have several questions for their prescribing physician including assurance of continued symptom management or ease of returning to the 5-ASA if needed.

It is unexpected that patients with stable lymphocytes on one fumarate would experience significant changes when switching to another fumarate; however, this was being observed in clinical practice. We wanted to identify the frequency and severity of lymphopenia after switching from dimethyl fumarate to either diroximel fumarate (DRF) or monomethyl fumarate (MMF). Our study determined that patients switching to DRF were more likely to have decreased lymphocyte counts post switch compared to MMF.

Given the high efficacy rates of DAA treatment in patients following NAT+ HCT SOT in HCV-recipients, little data is available to guide retreatment selection. This study aims to fill this gap by polling data from multiple treatment sites, assessing the retreatment strategies and SVC rates of said strategies.

Many barriers prevent individuals with substance use disorders from receiving hepatitis C virus (HCV) treatment. This study describes 96 patients with active HCV treated in an opioid use disorder bridge clinic model. Of 33 patients who initiated treatment, 25 patients completed treatment, and 13 patients achieved sustained virologic response.

In a cohort study of 61 patients prescribed risankizumab (RZB) for Crohn's Disease more frequently than the FDA approved dose, almost half had improvement. There was a trend suggesting patients who failed multiple advanced therapies were less likely to improve. A third (33%) of patients had additional medication changes. With available data, improvements were seen in CRP (54%), ESR (46%), and HBI (56%) measures. This study provides the largest cohort of escalated dosing in RZB.